Xanomeline-trospium found efficacious among schizophrenia patients experiencing acute psychosis: JAMA
Researchers discovered that xanomeline-trospium, a new-generation antipsychotic devoid of D2 dopamine receptor blocking activity, has shown potency and tolerance in patients with schizophrenia who present with acute psychosis. A recent study was conducted by Inder Kaul and colleagues. This study was published in JAMA Psychiatry.
Schizophrenia affects millions of people worldwide, with current treatments often limited by side effects, including weight gain, sedation, and movement disorders due to D2 dopamine receptor blockade. Xanomeline-trospium combines xanomeline, a dual M1/M4 muscarinic receptor agonist, with trospium chloride, a peripheral muscarinic receptor antagonist, to enhance tolerability.
The EMERGENT-3 clinical trial was a 5-week, multicenter, double-blind, randomized, placebo-controlled study performed at 30 inpatient sites in the US and Ukraine. A total of 256 adults with schizophrenia and acute psychosis were randomized 1:1 to xanomeline-trospium (maximum dose: 125 mg/30 mg) or placebo. The main measure of outcome was the change in Positive and Negative Syndrome Scale (PANSS) total score at week 5 compared with baseline. Secondary measures were changes in PANSS subscale scores and Clinical Global Impression–Severity (CGI-S) scores.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.